Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | KDM6A | O15550 | 1/20 | 0.56 |
| ▸ | TET3 | O43151 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.56 |
| ▸ | KDM4B | O94953 | 1/20 | 0.56 |
| ▸ | KDM5C | P41229 | 1/20 | 0.56 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.56 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.56 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.56 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.56 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9139640 | 0.98 | ALDH1A1 (0.97) | ALDH1A1EGLN1LMNAALOX12KDM4E | |
| SCHEMBL27872555 | 0.87 | ALDH1A1 (0.77) | ALDH1A1EGLN1LMNAKDM4EHSP90AA1 | |
| SCHEMBL2143721 | 0.84 | ALDH1A1 (0.73) | ALDH1A1EGLN1LMNAKDM4EHSP90AA1 | |
| SCHEMBL253460 | 0.84 | ALDH1A1 (0.73) | ALDH1A1EGLN1 | |
| SCHEMBL8885906 | 0.84 | ALDH1A1 (0.73) | ALDH1A1EGLN1LMNAKDM4EHSP90AA1 | |
| SCHEMBL2143864 | 0.84 | ALDH1A1 (0.73) | ALDH1A1EGLN1LMNAKDM4EHSP90AA1 | |
| SCHEMBL31023212 | 0.83 | ALDH1A1 (0.71) | ALDH1A1EGLN1LMNAALOX12 | |
| SCHEMBL6487277 | 0.83 | ALDH1A1 (0.71) | ALDH1A1EGLN1LMNAALOX12 | |
| SCHEMBL69869 | 0.82 | ALDH1A1 (0.70) | ALDH1A1EGLN1LMNAALOX12KDM4E | |
| SCHEMBL8885465 | 0.82 | ALDH1A1 (0.70) | ALDH1A1EGLN1LMNAKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | UNIV JIMEI (CN) | 2025-09-04 | — | — | US | claimed |
| US-12377086-B2 | Therapeutic methods, combinations and kits | Sham, Yuk Yin (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | claimed |
| CN-117883445-A | Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor | 集美大学 | 2024-04-16 | — | — | CN | claimed |
| US-20220401432-A1 | THERAPEUTIC METHODS, COMBINATIONS AND KITS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-12-22 | — | — | US | claimed |
| CN-115224271-A | Method for in-situ construction of zinc cathode artificial interface layer by simple soaking method | 南通大学 | 2022-10-21 | — | — | CN | claimed |
| US-20220280494-A1 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | DELPOR, INC. | 2022-09-08 | — | — | US | claimed |
| EP-4021406-A1 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | Delpor, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114641291-A | Compositions of small molecule therapeutic compounds | 戴尔普尔有限公司 | 2022-06-17 | — | — | CN | claimed |
| WO-2021041730-A1 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | DELPOR, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| WO-2018057968-A1 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | DELPOR, INC. (US) | 2018-03-29 | — | — | WO | claimed |
| WO-2018057977-A1 | STABLE COMPOSITIONS FOR INCRETIN MIMETIC COMPOUNDS | DELPOR, INC. (US) | 2018-03-29 | — | — | WO | claimed |
| US-7989129-B2 | Hydroxyquinoline containing photoconductors | XEROX CORPORATION (US) | 2011-08-02 | — | — | US | claimed |
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090246662-A1 | HYDROXYQUINOLINE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-10-01 | — | — | US | claimed |
| US-7479497-B2 | Use of quinoline derivatives with anti-integrase effect and applications thereof | BIOALLIANCE PHARMA SA (FR) | 2009-01-20 | — | — | US | claimed |
| US-20080207673-A1 | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins | XILINAS MICHEL | 2008-08-28 | — | — | US | claimed |
| US-20080161350-A1 | USE OF QUINOLINE DERIVATIVES WITH ANTI-INTEGRASE EFFECT AND APPLICATIONS THEREOF | BIOALLIANCE PHARMA SA | 2008-07-03 | — | — | US | claimed |
| WO-2006117660-A2 | METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS | CLIO PHARMACEUTICAL CORPORATION (US) | 2006-11-09 | — | — | WO | claimed |
| US-20050261336-A1 | Use of quinoline derivatives with anti-integrase effect and applications thereof | BIOALLIANCE PHARMA SA | 2005-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | XDH, DAO, KMO | ALDH1A1 635/4885EGLN1 1642/4885LMNA 3160/4885 |
| US-20220401432-A1 | THERAPEUTIC METHODS, COMBINATIONS AND KITS | MMP8, TLR7, GOT2 | ALDH1A1 465/4885EGLN1 1717/4885LMNA 2213/4885 |
| US-20050261336-A1 | Use of quinoline derivatives with anti-integrase effect and applications thereof | TYMP, CDK7, EIF2AK2 | ALDH1A1 919/4885EGLN1 2892/4885LMNA 1234/4885 |
| US-12377086-B2 | Therapeutic methods, combinations and kits | MMP8, TLR7, GOT2 | ALDH1A1 465/4885EGLN1 1717/4885LMNA 2213/4885 |
| US-20080161350-A1 | USE OF QUINOLINE DERIVATIVES WITH ANTI-INTEGRASE EFFECT AND APPLICATIONS THEREOF | TYMP, CDK7, MAVS | ALDH1A1 853/4885EGLN1 2731/4885LMNA 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.